Dermata Therapeutics, Inc. (DRMA) Form 8-K — Aug 11, 2026
Dermata Therapeutics reported a second quarter 2026 net loss of $3.0 million, or $0.74 per share, versus a $1.7 million loss ($1.66 per share) a year earlier, as selling, general and administrative expenses more than doubled to $2.8 million ahead of its first commercial product launch. Cash and equivalents stood at $4.4 million at June 30, 2026, down from $7.5 million at year-end 2025, and management expects current resources to fund operations only into the fourth quarter of 2026, pointing to a likely near-term capital raise. Roughly $1.9 million of ATM proceeds partially offset $4.9 million of operating cash burn in the first half of the year.
Key figures
- Cash Position
- 4413000
- Equity
- 3488000
- Cash runway
- sufficient to fund operations into the fourth quarter of 2026
- Total assets
- 5321000
- Total liabilities
- 1833000
- Rnd expense q2 2025
- 618000
- Rnd expense q2 2026
- 213000
- Sga expense q2 2025
- 1155000
- Sga expense q2 2026
- 2801000
- Cash decrease six months
- 3100000
- Cash position dec 31 2025
- 7522000
- First product launch date
- 2026-08-25
- Weighted avg shares q2 2025
- 1026506
- Weighted avg shares q2 2026
- 4022143
- Atm financing proceeds six months
- 1900000
- Cash used in operations six months
- 4900000
Price after filing
Close on the filing date to close N calendar days later (from $1.12). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.